Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$120.00
▼ $3.98 (-3.2%)
Market data updated: 09/19 10:27 AM
Fundamentals updated: 09/18/2026
News analyzed: 09/19/2026
Market Cap
$26.21B
Day Range
$119.40 - $124.11
52-Week Range
$90.39 - $212.75
Beta
—
Next Earnings
28.10.2026
Support
$96.42
Resistance
$137.70
INSM is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-17.7% (1Y)
Strengths: 7/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 66.7%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: -$124.21 vs. price $120.00 (-203.5%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
45
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
40
Quality
42
Value
38
Momentum
44
Risk
48
Sentiment
100
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Insmed Incorporated highlights its strong financial performance and strategic momentum. The company has seen a dramatic revenue surge—up 296% year-over-year in Q2 2026—alongside a significant reduction in net losses, signaling a pivotal turnaround. Analysts have rated Insmed a "Strong Buy" with a $175 price target, citing substantial long-term growth potential. Additionally, the company is showcasing new respiratory therapy data at the European Respiratory Society Congress, including late-breaking results for ARIKAYCE®, while expanding its workforce with inducement grants. Investor optimism remains high despite short-term challenges.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Insmed Incorporated. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
17
🎯 Conviction (vs. Emotion)
38
Psychology
52
Fundamentals
30
Technical
44
Valuation
38
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+25%
Market Narrative
63
Fundamental Reality
38
Narrative Gap
+25
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
Market behavior suggests a dominant *herding* dynamic, where investors align with peers despite modest underperformance. The 100/100 news sentiment and euphoric positioning (+6.2% above 200-day avg) imply optimism persists, even as momentum lags. The narrative-reality gap (22) hints at overestimation of fundamentals. Key question: Will sentiment sustain despite negative price momentum?
Updated: 09/09/2026, 05:12 AM
What could change this?
👥 What the crowd believes
"Total revenue hit $425.5 million, up 296% from the same quarter of 2025"
"Insmed announced the granting of inducement awards to 128 new employees under NASDAQ Listing Rule 5635(c)(4)"
"Insmed is rated Strong Buy with a $175 target, offering ~39% upside from current levels"
"five abstracts highlighting data from its respiratory portfolio... accepted for presentation at the European Respiratory Society Congress 2026"
📈 10D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 87/100
🔴 Weakest match
Thorstein Veblen — 12/100
🗣️ Why do they disagree?
The stark divide in verdicts for INSM reflects deep methodological differences in how these investors assess risk, market psychology, and valuation. Walter Bagehot’s high score highlights liquidity as a stabilizing factor, suggesting resilience in a downturn, while the majority of value-oriented investors—like Graham, Smith, and Lynch—rank it lower due to weak margin-of-safety signals or lack of clear growth potential. Meanwhile, behavioral economists like Veblen and Marks (cycle) flag speculative overreach or late-cycle risks, contrasting sharply with Mackay’s cautious optimism about crowd-driven momentum. The efficient-market camp and Schwager’s neutral stance imply no clear alpha opportunity, while Livermore’s indecision underscores a lack of decisive trend confirmation. The spectrum spans from defensive liquidity (Bagehot) to outright skepticism (Veblen), illustrating how even similar scores (e.g., Loeb’s 53 and Efficient-Market’s 53) can reflect vastly different risk tolerances—one prioritizing capital preservation, the other questioning active selection.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 87
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 76
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 72
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 70
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 54
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 50
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 46
Mixed — doesn't clearly pass Graham's tests
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 45
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 40
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 40
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 33
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 27
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 17
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 15
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 12
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (3 bullish · 6 bearish · 2 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
79.7%
Operating Margin
-205.6%
Net Margin
-210.5%
EBITDA Margin
-205.6%
ROE
-172.8%
ROA
-56.4%
ROIC
—
EPS
-$6.42
Cash
$510.44M
Total Debt
$540.96M
Current Ratio
3.83
Debt/Equity
0.73
How is Fair Value calculated? →
Current Price
$120.00
Estimated Fair Value (DCF)
-$124.21
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-203.5%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $-1.21B | $-1.11B |
| 2 | 19.4% | $-1.44B | $-1.22B |
| 3 | 13.8% | $-1.64B | $-1.27B |
| 4 | 8.1% | $-1.78B | $-1.26B |
| 5 | 2.5% | $-1.82B | $-1.18B |
Base FCF (last actual year)
$-967.58M
Terminal Value
$-28.70B
Present Value of Terminal Value
$-18.65B
Enterprise Value
$-24.69B
Net Debt
$30.52M
Equity Value
$-24.72B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3.71
Tangible Book Value per Share (Tangible NAV)
$2.54
Sentiment based on basic keywords (not AI) — 10 positive, 9 neutral, 1 negative out of the last 20 articles.
SeekingAlpha · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Benzinga · 15.9.2026
ChartMill · 15.9.2026
SeekingAlpha · 15.9.2026
SeekingAlpha · 14.9.2026
Yahoo · 11.9.2026
Zacks · 11.9.2026
Yahoo · 10.9.2026
Zacks · 10.9.2026
Yahoo · 10.9.2026
Insider Monkey · 10.9.2026
SeekingAlpha · 9.9.2026
SeekingAlpha · 8.9.2026
Benzinga · 7.9.2026
Yahoo · 4.9.2026
PR Newswire · 4.9.2026
Yahoo · 3.9.2026
PR Newswire · 3.9.2026
Insmed Incorporated (INSM) currently has a StockIQ AI score of 45/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
INSM currently scores 45/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, INSM's estimated fair value is -$124.21, which is 203.5% below the current price of $120.00. This is one valuation model among several signals in the fair-value category, not a price target.
INSM's technical score is 44/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 66.7%; Current ratio: 3.83; Price is above the 50-day average.
Based on the real signals StockIQ computed: Estimated fair value: -$124.21 vs. price $120.00 (-203.5%); Operating margin: -205.6% (negative); Net margin: -210.5% (negative).
StockIQ has no recorded dividend payment history for INSM.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 8 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Brennan David R | Open Market Sale | 9.9.2026 | 25,000 | -25,000 | $124.00 |
| SHAROKY MELVIN MD | Open Market Sale | 17.8.2026 | 5,000 | -5,000 | $127.53 |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 80,970 | +80,970 | $30.46 |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 76,600 | -76,600 | — |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 80,970 | -80,970 | — |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 76,600 | +76,600 | $17.16 |
| Adsett Roger | Open Market Sale | 10.8.2026 | 239,850 | -239,850 | $133.27 |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 82,280 | +82,280 | $13.67 |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 82,280 | -82,280 | — |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 181,024 | +82,280 | $13.67 |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 257,624 | +76,600 | $17.16 |
| Adsett Roger | Open Market Sale | 10.8.2026 | 98,744 | -239,850 | $133.27 |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 338,594 | +80,970 | $30.46 |
| Adsett Roger | Exercise of Derivative Securities | 10.8.2026 | 0 | -82,280 | — |
| Flammer Martina M.D. | Exercise of Derivative Securities | 6.8.2026 | 18,278 | +18,278 | $18.95 |
| Flammer Martina M.D. | Exercise of Derivative Securities | 6.8.2026 | 18,278 | -18,278 | — |
| Flammer Martina M.D. | Open Market Sale | 6.8.2026 | 8,895 | -8,895 | $127.00 |
| Flammer Martina M.D. | Open Market Sale | 6.8.2026 | 18,278 | -18,278 | $129.40 |
| Flammer Martina M.D. | Exercise of Derivative Securities | 6.8.2026 | 8,895 | -8,895 | — |
| Flammer Martina M.D. | Exercise of Derivative Securities | 6.8.2026 | 8,895 | +8,895 | $25.83 |
| Flammer Martina M.D. | Exercise of Derivative Securities | 6.8.2026 | 78,764 | +18,278 | $18.95 |
| Flammer Martina M.D. | Exercise of Derivative Securities | 6.8.2026 | 87,659 | +8,895 | $25.83 |
| Flammer Martina M.D. | Open Market Sale | 6.8.2026 | 78,764 | -8,895 | $127.00 |
| Flammer Martina M.D. | Open Market Sale | 6.8.2026 | 60,486 | -18,278 | $129.40 |
| Flammer Martina M.D. | Exercise of Derivative Securities | 6.8.2026 | 36,555 | -18,278 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
11,440,176 shares short as of 2026-08-31 · vs. 11,350,580 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
57.4% of trading volume this week was short selling, vs. 51.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology